Anebulo Pharmaceuticals Inc (NASDAQ: ANEB)’s stock price has plunge by 24.11relation to previous closing price of 1.12. Nevertheless, the company has seen a 32.38% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-02-14 that AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the in.
Is It Worth Investing in Anebulo Pharmaceuticals Inc (NASDAQ: ANEB) Right Now?
The 36-month beta value for ANEB is at -1.04. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANEB is 24.43M, and currently, shorts hold a 0.27% of that float. The average trading volume for ANEB on March 12, 2025 was 31.90K shares.
ANEB’s Market Performance
The stock of Anebulo Pharmaceuticals Inc (ANEB) has seen a 32.38% increase in the past week, with a -11.46% drop in the past month, and a -2.11% fall in the past quarter. The volatility ratio for the week is 25.78%, and the volatility levels for the past 30 days are at 13.40% for ANEB. The simple moving average for the last 20 days is 10.78% for ANEB stock, with a simple moving average of -24.38% for the last 200 days.
ANEB Trading at -4.36% from the 50-Day Moving Average
After a stumble in the market that brought ANEB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.88% of loss for the given period.
Volatility was left at 13.40%, however, over the last 30 days, the volatility rate increased by 25.78%, as shares sank -5.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.20% lower at present.
During the last 5 trading sessions, ANEB rose by +32.38%, which changed the moving average for the period of 200-days by -53.67% in comparison to the 20-day moving average, which settled at $1.2548. In addition, Anebulo Pharmaceuticals Inc saw -17.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANEB starting from English Aron R., who purchase 10,101,010 shares at the price of $0.99 back on Dec 23 ’24. After this action, English Aron R. now owns 15,467,300 shares of Anebulo Pharmaceuticals Inc, valued at $10,000,000 using the latest closing price.
Stock Fundamentals for ANEB
The total capital return value is set at -0.52. Equity return is now at value -71.49, with -65.70 for asset returns.
Currently, EBITDA for the company is -8.05 million with net debt to EBITDA at 2.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.52.
Conclusion
In conclusion, Anebulo Pharmaceuticals Inc (ANEB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
